An observational, prospective cohort study to evaluate the long term safety and effectiveness of intravenous CT-P13 (biosimilar of infliximab) in patients with Crohn's Disease or Ulcerative Colitis

被引：1
|
作者：
Cheon, J. H. [1 ,2 ]
Kang, H. W. [3 ]
Lee, S. J. [4 ]
Kim, S. H. [5 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea
[3] SMG SNU Boramae Med Ctr, Div Gastroenterol & Hepatol, Dept Internal Med, Seoul, South Korea
[4] CELLTRION Inc, Div Clin Dev, Incheon, South Korea
[5] CELLTRION Inc, Clin Planning, Incheon, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.482
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P358
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [1] Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis
    Gheorghe, Cristian
    Svoboda, Pavel
    Mateescu, Bogdan
    JOURNAL OF DRUG ASSESSMENT, 2019, 8 (01) : 129 - 134
  • [2] The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis
    Meyer, Antoine
    Rudant, Jeremie
    Drouin, Jerome
    Coste, Joel
    Carbonnel, Franck
    Weill, Alain
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (03) : 269 - 277
  • [3] Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
    Keil, Radan
    Wasserbauer, Martin
    Zadorova, Zdena
    Hajer, Jan
    Drastich, Pavel
    Wohl, Pavel
    Benes, Marek
    Bojkova, Martina
    Svoboda, Pavel
    Konecny, Michal
    Falt, Premysl
    Vanasek, Tomas
    Pesta, Martin
    Pesek, Frantisek
    Bouchner, Ludek
    Kozeluhova, Jana
    Novotny, Ales
    Bartuskova, Lucie
    Spicak, Julius
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) : 1062 - 1068
  • [4] Infliximab biosimilar CT-P13 in Crohn's disease
    Gecse, Krisztina B.
    D'Haens, Geert R.
    LANCET, 2019, 393 (10182): : 1671 - 1672
  • [5] Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis
    Hanzel, Jurij
    Bukkems, Laura H.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    Mathot, Ron A. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1309 - 1319
  • [6] A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
    Campochiaro, Corrado
    Tomelleri, Alessandro
    Sartorelli, Silvia
    Sembenini, Camilla
    Papa, Maurizio
    Fallanca, Federico
    Picchio, Maria
    Cavalli, Giulio
    De Cobelli, Francesco
    Baldissera, Elena
    Dagna, Lorenzo
    FRONTIERS IN MEDICINE, 2021, 8
  • [7] A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's disease and ulcerative colitis
    Ben-Horin, S.
    Leszczyszyn, J.
    Dudkowiak, R.
    Lahat, A.
    Gawdis-Wojnarska, B.
    Pukitis, A.
    Horynski, M.
    Farkas, K.
    Kierkus, J.
    Kowalski, M.
    Ye, B. D.
    Reinisch, W.
    Lee, S. J.
    Kim, S. H.
    Kim, M. R.
    Kim, Y. A.
    Kim, H. N.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S021 - S022
  • [8] Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study)
    Laharie, David
    Bouhnik, Yoram
    Vuitton, Lucine
    Biron, Amelie
    Pierron, Gaelle
    Brault, Yves
    Assing, Maryse
    Bouzidi, Amira
    Amiot, Aurelien
    Nancey, Stephane
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (10)
  • [9] Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
    Farkas, Klaudia
    Rutka, Mariann
    Balint, Anita
    Nagy, Ferenc
    Bor, Renata
    Milassin, Agnes
    Szepes, Zoltan
    Molnar, Tamas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (09) : 1257 - 1262
  • [10] COST-EFFECTIVENESS OF INFLIXIMAB'S BIOSIMILAR CT-P13 COMPARED TO INNOVATOR INFLIXIMAB FOR THE MANAGEMENT OF CROHN'S DISEASE.
    Beilman, Candace L.
    Ma, Christopher
    McCabe, Christopher
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2017, 152 (05) : S447 - S447
12345